OverviewSuggest Edit

Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. It enables physicians to deliver personalized cancer care for patients through interactive analytical and machine learning platform. Tempus provides genomic sequencing services and analyzes molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. The Company's goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as Tempus gathers more data. 
... Show more
TypePrivate
Founded2015
HQChicago, US
Websitetempus.com
Employee Ratings3.3

Latest Updates

Employees (est.) (Feb 2019)459(+5%)

Key People/Management at Tempus

Eric Lefkofsky

Eric Lefkofsky

Co-Founder and CEO
Kevin White

Kevin White

President
Gary Palmer

Gary Palmer

Chief Medical Officer
Nike Beaubier

Nike Beaubier

Director of Pathology and Medical Lab Operations
Erik Phelps

Erik Phelps

Executive Vice President and General Counsel
Shane Colley

Shane Colley

Senior Vice President of Engineering
Show more

Tempus Office Locations

Tempus has an office in Chicago
Chicago, US (HQ)
775 600 W Chicago Ave
Show all (1)
Report incorrect company information

Tempus Financials and Metrics

Summary Metrics

Founding Date

2015

Tempus total Funding

$320 m

Tempus latest funding size

$110 m

Time since last funding

6 months ago

Tempus investors

Tempus's latest funding round in August 2018 was reported to be $110 m. In total, Tempus has raised $320 m. Tempus's latest valuation is reported to be $2 b.
View all funding rounds

Tempus Revenue

Market valuation

2.0b
Show all financial metrics
Report incorrect company information

Tempus Online and Social Media Presence

Embed Graph
Report incorrect company information

Tempus News and Updates

Renovus Capital Partners Invests in Tempus Nova

WAYNE, Pa., Jan. 23, 2019 /PRNewswire/ -- Renovus Capital Partners ("Renovus") announced today that it has acquired a controlling interest in Tempus Nova ("TN" or the "Company"). Headquartered in Denver, CO, Tempus Nova is a trusted technology services partner to over 200 public and...

Tempus Energys banbrytande domstolsbeslut banar vägen för lägre priser och renare energi för kunder

LONDON, November 19, 2018 /PRNewswire/ -- Innovatören Tempus Energy lyckas utmana ensidigheten för fossila bränslen på den brittiska elmarknaden Kundfinansierade subventioner på 5,6 miljarder pund som gynnar förorenande fossila bränslen döms vara olagliga Domstolsbeslut banar väg för...

Tempus Energy's Groundbreaking Court Ruling Opens Door to Lower Prices and Cleaner Energy For Customers

LONDON, November 15, 2018 /PRNewswire/ -- Innovator Tempus Energy successfully challenges fossil fuel bias in UK power market £5.6bn committed in customer-funded subsidies favouring polluting fossil fuels ruled unlawful Ruling paves the way for cleaner, cheaper energy market Cleantech...
Report incorrect company information

Tempus Blogs

ASCO and Tempus Announce Collaboration to Help Research Sites Identify Potential Participants for the Targeted Agent and Profiling Utilization (TAPUR™) Study

ALEXANDRIA, Va. and CHICAGO, Jan. 10, 2019 (GLOBE NEWSWIRE) — The American Society of Clinical Oncology, Inc. (ASCO) and Tempus announced today an agreement to support research sites participating in ASCO’s Targeted Agent and Profiling Utilization (TAPUR™) Study. The TAPUR Study is a prospective, no…

Tempus Announces Next Phase of Biological Modeling Efforts

December 19 – Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced today an expansion of its biological modeling work to include profiling therapeutic responses across hundreds of unique patient derived organoid model…

Tempus Founder and CEO Eric Lefkofsky speaks with Bloomberg Businessweek’s Max Chafkin at Bloomberg’s The Year Ahead summit in New York.

Eric Lefkofsky and Max Chafkin discuss data-driven medicine. Video linked here.   The post Tempus Founder and CEO Eric Lefkofsky speaks with Bloomberg Businessweek’s Max Chafkin at Bloomberg’s The Year Ahead summit in New York. appeared first on Tempus.

Tempus Ramps Up AI-Driven Precision Oncology, Eyes Other Markets

Dec 03, 2018 | Neil Versel  CHICAGO (GenomeWeb) – Having raised some $320 million in funding since its launch in 2015, cancer informatics and precision medicine company Tempus continues to ramp up its clinical and molecular data collection and curation to support precision oncology, and is beginning…

Eric Lefkofsky and Dr. James Hamblin discuss using big data to fight cancer

Eric Lefkofsky and Dr. James Hamblin discuss using big data to fight cancer. Video linked here. The post Eric Lefkofsky and Dr. James Hamblin discuss using big data to fight cancer appeared first on Tempus.

Tempus and Mary Crowley Cancer Research Launch a New Lung Cancer Initiative

October 4 – Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data and Mary Crowley Cancer Research have announced a new collaboration with the objective of expanding research options for lung cancer patients. As part of t…
Show more

Tempus Company Life and Culture

Report incorrect company information

Tempus Frequently Asked Questions

  • When was Tempus founded?

    Tempus was founded in 2015.

  • Who are Tempus key executives?

    Tempus's key executives are Eric Lefkofsky, Kevin White and Gary Palmer.

  • How many employees does Tempus have?

    Tempus has 459 employees.

  • Who are Tempus competitors?

    Competitors of Tempus include InSilico Medicine, PeraHealth and AiCure.

  • Where is Tempus headquarters?

    Tempus headquarters is located at 775 600 W Chicago Ave, Chicago.

  • Where are Tempus offices?

    Tempus has an office in Chicago.

  • How many offices does Tempus have?

    Tempus has 1 office.